Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BLENREP vs AKEEGA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.
Niraparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP-1, PARP-2, and PARP-3, leading to DNA damage repair inhibition and apoptosis in BRCA-mutated cells. Abiraterone acetate is a prodrug converted to abiraterone, a CYP17A1 inhibitor that suppresses androgen biosynthesis in testicular, adrenal, and prostate tumor tissues.
FDA-approved for relapsed or refractory multiple myeloma in adults who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
Treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (germline and/or somatic) metastatic castration-resistant prostate cancer (m CRPC) in combination with prednisone.
2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
Recommended dose: 240 mg (niraparib) / 500 mg (abiraterone acetate) orally once daily with or without food.
The terminal elimination half-life of belantamab mafodotin is approximately 12 days (range 9-19 days). This supports a dosing interval of every 3 weeks, allowing for drug clearance between cycles while maintaining therapeutic exposure.
Terminal half-life: 17–30 hours (mean ~24 h); allows once-daily dosing but may require dose adjustment in renal impairment.
Belantamab mafodotin is likely metabolized via proteolytic degradation into small peptides and amino acids; MMAF is a substrate of CYP3A and P-glycoprotein, but the contribution of CYP3A to clearance is limited.
Niraparib is primarily metabolized by carboxylesterases (CEs) and to a lesser extent by CYP1A2 and CYP2D6. Abiraterone acetate is hydrolyzed to abiraterone, which is then metabolized by CYP3A4 and CYP2D6.
Blenrep (belantamab mafodotin) is eliminated primarily via catabolism, with no significant renal or biliary excretion of intact drug. The small molecule toxin, monomethyl auristatin F (MMAF), is excreted via feces (72%) and urine (28%) after release from the antibody conjugate.
Renal: ~85% (primarily as unchanged drug); Biliary/Fecal: ~15%.
Belantamab mafodotin is highly protein-bound (>99%) to plasma proteins, predominantly to albumin. The released MMAF is also extensively protein-bound (approximately 90% to albumin).
~99% (bound primarily to α1-acid glycoprotein and albumin).
The volume of distribution of belantamab mafodotin is approximately 7.8 L (range 4.5-12.4 L), which is slightly greater than plasma volume, indicating limited extravascular distribution. The Vd is not typically normalized to body weight; however, dosing is weight-based (mg/kg) to account for interpatient variability.
Vd: ~1.5–2.0 L/kg (indicates extensive tissue distribution).
Blenrep is administered as an intravenous infusion; thus, bioavailability is 100% by the intravenous route. No oral or other routes are approved.
Oral: ~90% (high oral bioavailability).
For moderate renal impairment (e GFR 30-59 m L/min/1.73 m²): reduce dose to 1.9 mg/kg. For severe renal impairment (e GFR 15-29 m L/min/1.73 m²): not recommended. For e GFR <15 m L/min/1.73 m²: contraindicated.
No dose adjustment required for mild to moderate renal impairment (e GFR ≥30 m L/min). Not recommended for severe renal impairment (e GFR <30 m L/min) or end-stage renal disease.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 1.9 mg/kg. Child-Pugh Class C: not recommended.
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment for mild (Child-Pugh class A) or moderate (Child-Pugh class B) impairment; but monitor closely for toxicity.
Safety and efficacy not established; no specific pediatric dosing guidelines available.
Safety and efficacy not established in pediatric patients; no recommended dose.
No specific dose adjustment recommended based on age alone; monitor renal function and consider dose adjustment per renal impairment guidelines.
No specific dose adjustment required. Clinical studies included patients ≥65 years; increased risk of adverse effects such as hypertension, hypokalemia, and fatigue. Monitor renal function and electrolytes regularly.
WARNING: OCULAR TOXICITY. Blenrep (belantamab mafodotin) causes severe ocular toxicity, including keratopathy and changes in visual acuity, which may require dose modification or discontinuation. Perform ophthalmic exams prior to each dose. Use only in patients who have received at least 4 prior therapies.
AKEEGA can cause severe and persistent hypertension, hypokalemia, and fluid retention due to mineralocorticoid excess, especially in patients with renal impairment. Monitor blood pressure, serum potassium, and fluid status regularly.
Ocular toxicity (keratopathy, visual acuity changes),Thrombocytopenia,Infusion-related reactions,Hepatotoxicity (increased transaminases),Embryo-fetal toxicity
Hypertension, hypokalemia, and fluid retention due to mineralocorticoid excess,Adrenocortical insufficiency,Hepatotoxicity,Cardiovascular effects including QT prolongation,Bone marrow suppression (anemia, thrombocytopenia, neutropenia),Fetal harm if used during pregnancy
None known
Concomitant use with strong CYP3A4 inducers,Severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease,History of hypersensitivity to niraparib, abiraterone, or any excipient
No specific food interactions known. Maintain adequate hydration.
Avoid food and beverages containing grapefruit, grapefruit juice, Seville oranges, and starfruit as they inhibit CYP3A4 and may increase abiraterone exposure. Take AKEEGA on an empty stomach (no food for at least 1 hour before or 2 hours after). Avoid high-fat meals as they increase abiraterone absorption.
FDA Pregnancy Category D. First trimester: belantamab mafodotin is an antibody-drug conjugate; the cytotoxic component may cause fetal harm. Second and third trimesters: risk of fetal toxicity and teratogenicity due to the microtubule inhibitor; avoid use unless maternal benefit outweighs risk.
AKEEGA (niraparib and abiraterone acetate) is contraindicated in pregnancy. Based on its mechanism of action and findings in animal studies, niraparib can cause fetal harm. Abiraterone acetate is also associated with fetal risks. First trimester exposure may cause embryofetal lethality and teratogenicity. Second and third trimester exposure may impair fetal adrenal function and androgen-dependent development.
No data on presence in human milk. M/P ratio unknown. Advise to discontinue breastfeeding during treatment and for at least 3 months after last dose due to potential for severe adverse reactions in breastfed infants.
No data on the presence of niraparib or abiraterone in human milk, effects on breastfed infants, or milk production. Due to the potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 1 month after the last dose. M/P ratio is unknown.
No specific dose adjustments in pregnancy established. Use is not recommended; if unavoidable, consider dose reduction based on tolerability (e.g., for ocular toxicity). No pharmacokinetic data available to guide adjustments.
No specific dose adjustments are established during pregnancy as AKEEGA is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) may necessitate dose adjustments if used inadvertently, but no data are available. If exposure occurs, cautious monitoring and individualized dosing are recommended.
Monitor for ocular toxicity, including keratitis and uveitis; perform ophthalmic exams at baseline and during therapy. Premedicate with corticosteroids and vasoconstrictors to reduce infusion reactions. Blenrep is a BCMA-directed antibody-drug conjugate for relapsed/refractory multiple myeloma. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min).
AKEEGA (niraparib and abiraterone acetate) is indicated for BRCA-positive metastatic castration-resistant prostate cancer. Monitor for myelosuppression (CBC at baseline and monthly), hypertension (BP weekly for first month then monthly), hypokalemia, and hepatotoxicity (LFTs at baseline and monthly). CYP3A4 inhibitors increase abiraterone exposure; avoid strong inhibitors or reduce dose. Corticosteroid co-administration (prednisone 5 mg BID) is required to manage mineralocorticoid excess. Niraparib may cause fetal harm; confirm pregnancy status before initiation.
Inform your doctor immediately if you experience blurred vision, eye pain, or light sensitivity.,You will need eye exams before and during treatment.,Report any signs of infusion reactions such as chills, fever, or difficulty breathing.,Use effective contraception during treatment and for 4 months after the last dose.,Avoid driving or operating machinery if you have vision changes.
Take tablets on an empty stomach, at least 1 hour before or 2 hours after a meal.,Swallow tablets whole; do not crush or chew.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit during treatment.,Use effective contraception during treatment and for 4 months after the last dose for females and 3 months for males.,Report signs of bone marrow suppression: fever, bruising, bleeding, or unusual tiredness.,Report symptoms of high blood pressure: severe headache, blurred vision, or chest pain.,Take prednisone exactly as prescribed; do not stop abruptly.,Avoid pregnancy; discuss fertility preservation options before starting treatment.,Take missed doses if within 12 hours of scheduled time; otherwise skip and resume next day.,Store at room temperature; keep in original container.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BLENREP vs AKEEGA, answered by our medical review team.
BLENREP is a Antineoplastic, Monoclonal Antibody that works by Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) on multiple myeloma cells. The monoclonal antibody component binds to BCMA, leading to internalization and release of the cytotoxic agent monomethyl auristatin F (MMAF), which disrupts microtubule polymerization and induces apoptosis.. AKEEGA is a Antineoplastic Combination that works by Niraparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP-1, PARP-2, and PARP-3, leading to DNA damage repair inhibition and apoptosis in BRCA-mutated cells. Abiraterone acetate is a prodrug converted to abiraterone, a CYP17A1 inhibitor that suppresses androgen biosynthesis in testicular, adrenal, and prostate tumor tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BLENREP and AKEEGA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BLENREP is: 2.5 mg/kg (actual body weight) intravenously over 30 minutes on day 1 of each 21-day cycle until disease progression or unacceptable toxicity.. The standard adult dose of AKEEGA is: Recommended dose: 240 mg (niraparib) / 500 mg (abiraterone acetate) orally once daily with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BLENREP and AKEEGA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BLENREP is classified as Category C. FDA Pregnancy Category D. First trimester: belantamab mafodotin is an antibody-drug conjugate; the cytotoxic component may cause fetal harm. Second and third trimesters: risk of fe. AKEEGA is classified as Category C. AKEEGA (niraparib and abiraterone acetate) is contraindicated in pregnancy. Based on its mechanism of action and findings in animal studies, niraparib can cause fetal harm. Abirate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.